☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MeReC Extra 27

The National Prescribing Centre (NPC) has published MeReC Extra 27 that provides a reminder of maximum doses of inhaled steroids in children, an analysis of the consequences of thiazide related diabetes and an analysis of the evidence supporting Grazax®.

Individual sections are available as follows:

The first section reminds clinicians of the licensed doses of inhaled steroids in children. A recent study has identified links between prescribing of high doses inhaled steroids in young children and adrenal suppression. An observational study of GP prescribing is cited that recommends audits are carried out to identify children at high risk of adverse outcomes.

The analysis of the consequences of thiazide-induced diabetes discusses the findings of a post-hoc subgroup analysis of the ALLHAT study. The analysis found no significant association between fasting glucose changes and any of the study endpoints (death, CV disease or end-stage renal disease) in a combined analysis or for thiazides alone. Further investigation is required but this finding adds some weight to a 14-year follow-up of another study that suggests any observed excess in diabetes does not increase cardiovascular risk.

Grazax is only indicated following a positive allergen test to grass pollen (skin prick or specific IgE test). It is recommended that physicians with experience in the treatment of allergic disease initiate treatment. The first dose should also be taken under medical supervision due to the risk of allergic reactions. It is also noted that the absolute benefits of Grazax are modest and have not been compared with subcutaneous allergen immunotherapy.

Action: Clinicians who treat children with asthma, hypertension or grass pollen allergy will find this MeReC useful and informative.

Share 'MeReC Extra 27' by emailShare 'MeReC Extra 27' on FacebookShare 'MeReC Extra 27' on TwitterShare 'MeReC Extra 27' on LinkedInShare 'MeReC Extra 27' on reddit


One Comment to “MeReC Extra 27”

  1. [...] previously discussed, it is recommended that initiation and treatment with Grazax is restricted to physicians who are [...]

    Pingback by Prescribing Advice for GPs » SMC reject Grazax and BuTrans — April 25, 2008 #

Leave a Reply to Prescribing Advice for GPs » SMC reject Grazax and BuTrans Cancel reply

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.